Purine and pyrimidine metabolism: still a black box? G. J. PetersJ. H. Beijnen Editorial Pages: 37 - 39
Clinical and biochemical aspects of uric acid overproduction J. García PuigF. Antón Mateos OriginalPaper Pages: 40 - 54
Release and actions of adenosine in the central nervous system M. J. HigginsH. HosseinzadehT. W. Stone OriginalPaper Pages: 62 - 68
Role of differentiation induction in action of purine antimetabolites George WeberYuki HataNoemi Prajda OriginalPaper Pages: 77 - 83
New targets for pyrimidine antimetabolites in the treatment of solid tumours C. L. van der WiltG. J. Peters OriginalPaper Pages: 84 - 103
New targets for pyrimidine antimetabolites for the treatment of solid tumours Veronique W. T. Ruiz van HaperenGodefridus J. Peters OriginalPaper Pages: 104 - 112
Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives Jan Balzarini OriginalPaper Pages: 113 - 126
Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review T. Kulikowski ReviewPaper Pages: 127 - 138
When and how does one search for inborn errors of purine and pyrimidine metabolism? H. A. Simmonds OriginalPaper Pages: 139 - 148